secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-277165
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements
--------------------------------------------------------------------------------

- Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.
- Cash and cash equivalents $164.3M; runway extended into 2026 via new loan with Trinity Capital (no financial covenants or warrants).
- TSHA-102 first two adult patients: well-tolerated, no SAEs; sustained improvements in autonomic, motor, socialization functions at week 12 (patient 1) and week 4 (patient 2).
- IDMC cleared dosing of third adult patient; low-dose cohort completion and first U.S. pediatric dosing expected Q1 2024.
- R&D expenses $11.8M (down from $16.8M YoY) due to lower headcount and licensing fees, partially offset by clinical trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/0001193125-23-277165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/d361794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer